taking aflasafe from science to scale
play

Taking Aflasafe from Science to Scale Ranajit Bandyopadhyay & - PowerPoint PPT Presentation

SCALE-UP CONFERENCE Purdue University, 25 - 27 September 2018 Taking Aflasafe from Science to Scale Ranajit Bandyopadhyay & Matieyedou Konlambigue International Institute of Tropical Agriculture (IITA) www.iita.org I www.cgiar.org


  1. SCALE-UP CONFERENCE Purdue University, 25 - 27 September 2018 Taking Aflasafe from Science to Scale Ranajit Bandyopadhyay & Matieyedou Konlambigue International Institute of Tropical Agriculture (IITA) www.iita.org I www.cgiar.org

  2. Importance of aflatoxins Aflatoxin B1 Aspergillus Occurrence 40% of commodities in Liver cancer local markets exceed ML Susceptible crops Maize, groundnuts, sorghum, Death cottonseed, chili, millet, figs, melon seed, ginger, sesame, cassava, almond, pistachio… Up to US$ 670 million are lost from exports www.iita.org I www.cgiar.org

  3. Biocontrol is a simple field intervention that effectively reduces aflatoxin contamination from farms until consumption Aflasafe • Constituent: mixture of 4 native non-toxic Aspergillus strains • Reduces aflatoxin in maize and groundnut by >80% • One application per season • Multi-crop & multi-season benefit • Application rate: 10 kg/ha • Cost: $12-19/ha • Willingness to pay: $11-19/ha www.iita.org I www.cgiar.org

  4. Proof of Concept • 32 agribusinesses Productivity: 3.1 • 49,500 farmers tons/ha compared to • 63,000 ha maize grown 1.5 tons/ha national • 600 tons Aflasafe average purchased Meets Grain lots (n = 2,362) with % international aflatoxin concentration standards <4 ppb 90% More <10 ppb 94% income <20 ppb 96% • 10.7% premium in More 194,310 tons of grains trade the market over harvested normal maize • 57% aggregated for sale Better • $1.491 million in net • 27% consumed at home health earning from • 16% sold in local market premium www.iita.org I www.cgiar.org

  5. Commercialization Path www.iita.org I www.cgiar.org

  6. WHAT HAVE WE LEARNED? This ‘’Invisible problem’’ requires significant investment on public awareness - and the enforcement of appropriate policies - The proof of concept in one country is essential but not sufficient to demonstrate the value of the product in all countries. - Timing of the investors forum: The demonstration at national level and the development of the Business cases earlier in year 1 may positively affect the success of investors mobilization - Ownership of the Business planning by the investor: From the strategy to the Business plan QUESTIONS? Management of the commercialization process: What is the right balance between the Business Development and the scientific work? How should business development approach differ between publicly funded innovations with public health benefits and privately funded innovations? What kind of institutional set up is required to sustain the gains and expand to other products? www.iita.org I www.cgiar.org

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend